Changling Capital completed the fund raising and is committed to investing in China's medical health and quality consumption

Arterial Network first learned that on July 24, 2018, Changling Capital announced that it had successfully completed the final fundraising of the second phase of the US dollar fund and the first delivery of the first phase of the RMB fund, totaling RMB 2 billion. Changling will continue its successful thematic investment strategy and invest in early and growing companies in the domestic healthcare and quality consumption sectors.

In the first half of 2018, China’s VC/PE fundraising scale showed a cliff-like decline. The acquisition of Changling Capital’s second-phase US dollar fund took less than three months and $265 million was raised. The scale is significantly larger than the original target. The fund's investors include many world-renowned pension funds, endowments, foundations, financial institutions, family offices and parent funds. The first phase of the RMB fund has also received support from a number of institutional investors including state-level venture capital guiding funds, market-based parent funds, and well-known family offices. After the completion of the new dual-currency fund, the total fund managed by Changling Capital has reached RMB 3 billion.

“Technological innovation is changing every industry in China, and unprecedented disruptive innovation opportunities have emerged in all areas we are deeply focusing on.” Jiang Xiaodong, founding managing partner of Changling Capital, said, “We are the theme-driven, industry-focused investment. Focusing on vertical segments allows us to screen out exciting investment opportunities earlier and become the best partner for entrepreneurs."

Since its inception in 2016, Changling Capital has quickly become a leading investor in healthcare and quality consumption. 80% of the first-period US dollar funds were initially invested in Round A. In the past 18 months, the amount of subsequent rounds of financing completed by these projects totaled more than RMB 2 billion. In less than two years, there have been three Changling team A-investment projects currently valued at more than 5 billion yuan.

The vast majority of investors in the Changling Phase I US dollar fund continue to invest in the second phase of the fund. NEA Global Managing Partner Scott Sandell said: "Changling Capital's focus on medical health and quality consumption is consistent with NEA's global strengths. We have been working with Mr. Jiang Xiaodong for more than 13 years and look forward to a longer life with Changling Capital in the future. Close cooperation."

“Changling Capital’s deep understanding of the industry and its unique research-driven investment approach have given them a strong competitive advantage,” said Rebecca Xu, Managing Director of Asia Alternatives. “We have achieved very good results for Changling Capital in the past two years. Satisfied, and I am proud to be the cornerstone investor who has been from the beginning of Changling."

Founded in 2016, Changling Capital is a new generation of theme-driven venture capital fund in China. It currently manages RMB 2 billion in dual-currency capital and is committed to investing in technological advancement and business innovation that bring health and quality to life for every Chinese. The founder of Changling Capital comes from NEA, one of the largest venture capital funds in the United States. From 2005 to 2015, he was responsible for NEA's investment in China and successfully achieved more than $500 million. Changling Capital Investment Team members come from China's outstanding early-stage venture capital funds including NEA, Jingwei Venture Capital, Morningside Capital, etc., with more than 40 years of experience in Chinese local venture capital, and the most successful technology and medical care in China. The company has more than 20 years of operational experience.

Amino Acid

Amino acid

Amino acid,Acetylcysteine,l-Theanine,L-cysteine,l-carnitine,L-Glutamine

PYSON Co. ,Ltd. , https://www.pysonbio.com